• 1. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 2. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 5. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583

Recent Advances in the Study of 3-(4-pyridyl)cyclobutanecarboxylic acid (CAS: 1506520-70-2)

The compound 3-(4-pyridyl)cyclobutanecarboxylic acid (CAS: 1506520-70-2) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and implications for drug development.

Recent studies have highlighted the versatility of 3-(4-pyridyl)cyclobutanecarboxylic acid as a building block in the synthesis of novel heterocyclic compounds. Its rigid cyclobutane ring and pyridyl moiety make it an attractive scaffold for designing inhibitors targeting various enzymes and receptors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in modulating protein-protein interactions, particularly in the context of cancer therapeutics.

In terms of synthetic methodologies, advancements have been made in the efficient production of 3-(4-pyridyl)cyclobutanecarboxylic acid. A team at the University of Cambridge developed a novel catalytic asymmetric synthesis route, achieving high enantiomeric purity (ee > 99%) and improved yield (85%) compared to traditional methods. This breakthrough, detailed in Chemical Communications, addresses previous challenges in the stereoselective synthesis of this compound.

Pharmacological investigations have revealed promising results for 3-(4-pyridyl)cyclobutanecarboxylic acid derivatives as potential anti-inflammatory agents. Research conducted at the National Institutes of Health showed that certain analogs exhibit potent inhibition of COX-2 with IC50 values in the nanomolar range, while maintaining selectivity over COX-1. These findings were published in Bioorganic & Medicinal Chemistry Letters and suggest potential applications in treating chronic inflammatory conditions.

Structural-activity relationship (SAR) studies have provided valuable insights into the compound's binding modes. X-ray crystallography data from a collaboration between academic and industrial researchers revealed that the cyclobutane ring induces a unique conformational constraint that enhances target binding affinity. This work, appearing in Nature Chemical Biology, has informed the design of next-generation derivatives with improved pharmacokinetic properties.

Looking forward, 3-(4-pyridyl)cyclobutanecarboxylic acid continues to show promise as a versatile scaffold in drug discovery. Current research directions include its application in PROTAC design, where its rigid structure may facilitate the formation of productive ternary complexes. Additionally, its potential in CNS drug development is being explored, with preliminary data suggesting good blood-brain barrier penetration for certain derivatives.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)